L03 Use and impact of neuroleptics in Huntington's disease: a prospective cohort study of the Huntington French speaking group

Dolbeau, G; Lombard, A; Youssov, K; Dürr, A; Charles, P; Verny, C; Azulay, J-P; Krystkowiak, P; Simonin, C; Tranchant, C; Goizet, C; Damier, P; Supiot, F; Broussolle, E; Démonet, J-F; Marie, R-M; Verin, M; Bachoud-Lévi, A-C; Maison, P
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA48
Academic Journal
Background Recent reviews of available drug trials and case reports conclude that the guidelines for the treatment of Huntington's disease (HD) symptoms are scarce. Aims We wanted to better understand the use of neuroleptics and related drugs (NL-R) in HD by observing their use in clinical practice and their impact on disease progression. Methods/techniques We explored and compared the profile and evolution of patients treated by NL-R in the cohort of the Huntington French Speaking Group Cohort. This cohort comparative study included 760 patients with available CAG repeats and medication information, followed for 22.4 (±23.3) months between 2002 and 2010. Results/outcome 63% of patients were treated by a NL-R at least once during the follow up. The main NL-R used by the clinicians were (before and after 2006, respectively): olanzapine (38.8 vs 34.5%, NS), risperidone (15.2 vs 16.0%, NS), tiapride (9.4 vs 8.5%, NS) and tetrabenazine (0.8 vs 18.9%, p<0.001). Profiles differed by chorea (p<0.05), UHDRS Functional Assessment Scale (FAS), Total Functional Capacity (TFC) (p<0.05) and Independence Scale (IS) (p<0.01), with patients taking olanzapine being less disabled on the functional scales. Conversely, tiapride was provided to the most advanced patients. The risperidone group displayed the lowest chorea score (8.4±5.4). During treatment, effectiveness adjusted for baseline profile was statistically different between NL-R. Changes in clinical evolution differed for TFC and FAS (p<0.05) and for body mass index (BMI) (p<0.001). Patients under tiapride displayed the slower functional decline and patients with tetrabenazine were the only one where BMI decreased (3.4±5.7%/year). Conclusion In our cohort study of 760 HD patients, the four main NL-R used in HD (olanzapine, risperidone, tiapride and tetrabenazine) seem to have different effectiveness on the progression of the disease.


Related Articles

  • Huntington's Disease.  // World Book Science Dataset;1/1/2009, p1 

    Huntington's Disease

  • Putting Huntingtin Aggregation in View with Windows into the Cellular Milieu. Hatters, Danny M. // Current Topics in Medicinal Chemistry;Nov2012, Vol. 12 Issue 22, p2611 


  • Monitoring Reportable Events and Unanticipated Problems: The PHAROS and PREDICT Studies of Huntington Disease. Erwin, Cheryl; Hersch, Steven // IRB: Ethics & Human Research;May/Jun2007, Vol. 29 Issue 3, p11 

    The article reports on the events and unanticipated problems faced during the two observational studies for Huntington disease in the U.S. These include the Prospective Huntington At Risk Observational Study (PHAROS) and the Neurobiological Predictors of Huntington Disease (PREDICT-HD) by the...

  • Tetrabenazine/tiapride.  // Reactions Weekly;Jul2014, Vol. 1508 Issue 1, p35 

    The article presents a case study of an 81-year-old woman who was diagnosed with neuroleptic malignant syndrome (NMS) while being treated with tiapride and tetrabenazine for Huntington's disease (HD).

  • Seventh Annual Huntington Disease Clinical Research Symposium.  // Neurotherapeutics;Jan2014, Vol. 11 Issue 1, p213 

    The article offers information on the Seventh Annual Huntington Disease Clinical Research Symposium, organized by the Huntington Study Group, clinical researchers who care for the disease, held at the Omni Charlotte Hotel in Charlotte, North Carolina on November 9, 2013. Topics of discussion...

  • Rationing research. D.L. // Common Cause Magazine;Winter95, Vol. 21 Issue 4, p6 

    Presents information on the Huntington's diseases. When it starts to affect the body; Sufferers awareness; Huntington's research funding; Progress; Impact of the disease on the life of Betty Lichtenberg.

  • Aripiprazole.  // Reactions Weekly;12/4/2010, Issue 1330, p9 

    The article describes a case study of a 55-year-old man who experienced neuroleptic malignant syndrome during treatment with aripiprazole 10 milligrams to treat his aggressive behavior associated with Huntington's disease, referencing a study published in the October 2010 issue of the...

  • Choreatische Bewegungsst�rungen. Kosinski, C.M.; Landwehrmeyer, B. // Nervenarzt;Sep2007, Vol. 78 Issue 0, p37 

    The differential diagnosis of chorea includes a growing number of rare diseases. This article gives hints on clinical differences and possible laboratory investigations which may help to identify the underlying disease. The majority of hereditary chorea cases are caused by Huntington's disease....

  • Psychological studies in Huntington's disease: making up the balance. Duisterhof, Magdalena; Trijsburg, Rutger W.; Niermeijer, Martinus F.; Roos, Raymund A. C.; Tibben, Aad // Journal of Medical Genetics;Dec2001, Vol. 38 Issue 12, p852 

    Presents a letter to the editor about psychological studies in Huntington's disease.


Read the Article


Sign out of this library

Other Topics